Cytosorbents Showcases Blood Purification Innovations at Jefferies Global Healthcare Conference
- CytoSorbents will present its blood purification innovations at the Jefferies Global Healthcare Conference on November 18, 2025.
- The flagship product, CytoSorb®, filters toxins from blood, enhancing patient care in critical environments like ICUs and surgeries.
- CytoSorb® is CE-marked, used in over 70 countries, and has nearly 300,000 devices deployed to improve patient outcomes.
CytoSorbents Advances Blood Purification Technologies in Critical Care
CytoSorbents Corporation, a leader in blood purification technologies, is poised to showcase its innovations at the upcoming Jefferies Global Healthcare Conference in London, scheduled for November 17-20, 2025. The company will provide an in-depth presentation on November 18 at 12:30 PM GMT, which will also be accessible via a live webcast. This event marks another significant opportunity for CytoSorbents to discuss its advancements in addressing life-threatening medical conditions through its proprietary blood purification technologies.
Cytosorbents specializes in utilizing biocompatible, porous polymer beads that effectively eliminate toxic substances from blood and bodily fluids, enhancing patient care in intensive care units and cardiac surgery environments. The company's flagship product, CytoSorb®, is designed to integrate seamlessly with existing hospital blood pumps, such as dialysis and ECMO machines, enabling healthcare providers to filter harmful substances while ensuring blood is recirculated back into patients. This unique capability addresses critical health challenges, including the management of blood thinners during cardiothoracic surgery, which can significantly reduce the risk of excessive bleeding. Additionally, the technology is pivotal in filtering inflammatory agents in severe conditions like sepsis, trauma, and liver failure, ultimately helping to prevent organ failure and improve survival rates.
CytoSorbents' impact is underscored by the widespread adoption of its flagship product, which is CE-marked and available in over 70 countries. With nearly 300,000 devices used to date, CytoSorb® holds the distinction of being the first cytokine adsorber approved in the European Union. The company's commitment to innovation is not only reflected in its product distribution but also in its ongoing efforts to enhance patient outcomes in critical care settings, where effective treatment options are often scarce. As CytoSorbents prepares for its presentation at the Jefferies Global Healthcare Conference, it reinforces its position as a vital player in the medical field, focusing on solutions that save lives and improve the quality of care for patients facing dire health challenges.
In addition to its conference presentation, CytoSorbents continues to engage in strategic initiatives aimed at expanding its market reach and reinforcing its position as a leader in blood purification. The company remains dedicated to advancing its technologies and addressing the pressing needs of healthcare providers and patients alike. As the global healthcare landscape evolves, CytoSorbents stands ready to meet the challenges of critical care with innovative solutions designed to make a meaningful difference in patient outcomes.